Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Avenue Therapeutics stock | $1.33

Learn how to easily invest in Avenue Therapeutics stock.

Avenue Therapeutics Inc is a biotechnology business based in the US. Avenue Therapeutics shares (ATXI) are listed on the NASDAQ and all prices are listed in US Dollars. Avenue Therapeutics employs 4 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Avenue Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ATXI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Avenue Therapeutics stock price (NASDAQ: ATXI)

Use our graph to track the performance of ATXI stocks over time.

Avenue Therapeutics shares at a glance

Information last updated 2021-10-16.
Latest market close$1.33
52-week range$1.27 - $7.69
50-day moving average $1.55
200-day moving average $2.98
Wall St. target price$12.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.24

Buy Avenue Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Avenue Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Avenue Therapeutics price performance over time

Historical closes compared with the close of $1.33 from 2021-10-21

1 week (2021-10-13) 2.31%
1 month (2021-09-22) -13.07%
3 months (2021-07-22) -36.36%
6 months (2021-04-22) -71.34%
1 year (2020-10-22) -61.67%
2 years (2019-10-22) -75.60%
3 years (2018-10-22) 3.41
5 years (2016-10-18) N/A

Avenue Therapeutics financials

Gross profit TTM $0
Return on assets TTM -76.43%
Return on equity TTM -167.32%
Profit margin 0%
Book value $0.04
Market capitalisation $21.3 million

TTM: trailing 12 months

Shorting Avenue Therapeutics shares

There are currently 250,169 Avenue Therapeutics shares held short by investors – that's known as Avenue Therapeutics's "short interest". This figure is 10.2% down from 278,439 last month.

There are a few different ways that this level of interest in shorting Avenue Therapeutics shares can be evaluated.

Avenue Therapeutics's "short interest ratio" (SIR)

Avenue Therapeutics's "short interest ratio" (SIR) is the quantity of Avenue Therapeutics shares currently shorted divided by the average quantity of Avenue Therapeutics shares traded daily (recently around 61617.980295567). Avenue Therapeutics's SIR currently stands at 4.06. In other words for every 100,000 Avenue Therapeutics shares traded daily on the market, roughly 4060 shares are currently held short.

However Avenue Therapeutics's short interest can also be evaluated against the total number of Avenue Therapeutics shares, or, against the total number of tradable Avenue Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avenue Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Avenue Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0379% of the tradable shares (for every 100,000 tradable Avenue Therapeutics shares, roughly 38 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Avenue Therapeutics.

Find out more about how you can short Avenue Therapeutics stock.

Avenue Therapeutics share dividends

We're not expecting Avenue Therapeutics to pay a dividend over the next 12 months.

Avenue Therapeutics share price volatility

Over the last 12 months, Avenue Therapeutics's shares have ranged in value from as little as $1.27 up to $7.69. A popular way to gauge a stock's volatility is its "beta".

ATXI.US volatility(beta: 0.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avenue Therapeutics's is 0.6788. This would suggest that Avenue Therapeutics's shares are less volatile than average (for this exchange).

Avenue Therapeutics overview

Avenue Therapeutics, Inc. , a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York. .

Frequently asked questions

What percentage of Avenue Therapeutics is owned by insiders or institutions?
Currently 60.399% of Avenue Therapeutics shares are held by insiders and 6.867% by institutions.
How many people work for Avenue Therapeutics?
Latest data suggests 4 work at Avenue Therapeutics.
When does the fiscal year end for Avenue Therapeutics?
Avenue Therapeutics's fiscal year ends in December.
Where is Avenue Therapeutics based?
Avenue Therapeutics's address is: 1140 Avenue of the America, New York, NY, United States, 10036
What is Avenue Therapeutics's ISIN number?
Avenue Therapeutics's international securities identification number is: US05360L2051
What is Avenue Therapeutics's CUSIP number?
Avenue Therapeutics's Committee on Uniform Securities Identification Procedures number is: 05360L106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site